Heart Failure Reviews

, Volume 24, Issue 6, pp 997–1004 | Cite as

Cardiogenic shock in cancer

  • Kalliopi KeramidaEmail author
  • John T. Parissis
  • Ovidiu Chioncel
  • Dimitrios Farmakis


Cardiogenic shock (CS) is increasingly recognized in patients with malignancies, while cancer is independently associated with worse prognosis in CS. A number of conditions may lead to CS in cancer, including acute coronary syndromes, cardiomyopathy, takotsubo syndrome, myocarditis, pulmonary embolism, tamponade, and cardiac herniation. In these conditions, CS may be related to cancer itself or to cancer therapy, including surgery, chemotherapy, or radiotherapy. Given the significantly improved overall survival of patients with malignancies, the early recognition and proper management of CS in cancer become increasingly important. In the present paper, we review the available evidence on CS in patients with malignancies and highlight issues related to its management.


Cancer Cardiogenic shock Chemotherapy Radiotherapy 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Tubaro M, Vranckx P, Price S, Vrints C, European Society of C. The ESC textbook of intensive and acute cardiovascular care. 2016Google Scholar
  2. 2.
    Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Lopez-Fernandez S, Miani D, Filippatos G, Maggioni AP, on behalf of the ESC Heart Failure Long-Term Registry Investigators (2017) Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19(10):1242–1254PubMedGoogle Scholar
  3. 3.
    Puymirat E, Fagon JY, Aegerter P et al (2017) Cardiogenic shock in intensive care units: evolution of prevalence, patient profile, management and outcomes, 1997–2012. Eur J Heart Failure 19(2):192–200Google Scholar
  4. 4.
    Shaefi S, O’Gara B, Kociol RD, Joynt K, Mueller A, Nizamuddin J, Mahmood E, Talmor D, Shahul S (2015) Effect of cardiogenic shock hospital volume on mortality in patients with cardiogenic shock. J Am Heart Assoc 4(1):e001462PubMedPubMedCentralGoogle Scholar
  5. 5.
    Rodriguez M, Sabharwal B, Wei X, Krittanawong C, Verheyen E, Herzog E. The effect of cancer on outcomes on acute heart failure exacerbations: a 5-year nationwide analysis. 2018;71(11 Supplement):A693Google Scholar
  6. 6.
    Iliescu CA, Grines CL, Herrmann J et al (2016) SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of India, and sociedad Latino Americana de Cardiologia intervencionista). Catheter Cardiovasc Interv 87(5):E202–E223PubMedGoogle Scholar
  7. 7.
    Park JY, Al-Hijji M, El Sabbagh A et al (2016) Acute coronary syndrome in active hematological malignancies: a cohort study of 5,300 patients. JACC 67(13 Supplement):585Google Scholar
  8. 8.
    Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM (2017) Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 70(8):926–938PubMedPubMedCentralGoogle Scholar
  9. 9.
    Lim SH, Wilson SM, Hunter A, Hill J, Beale P (2013) Takotsubo cardiomyopathy and 5-fluorouracil: getting to the heart of the matter. Case Rep Oncol Med 2013:206765PubMedPubMedCentralGoogle Scholar
  10. 10.
    Rohrmann S, Witassek F, Erne P, Rickli H, Radovanovic D (2018) Treatment of patients with myocardial infarction depends on history of cancer. Eur Heart J Acute Cardiovasc Care 7(7):639–645PubMedGoogle Scholar
  11. 11.
    Velders MA, Boden H, Hofma SH, Osanto S, van der Hoeven BL, Heestermans AACM, Cannegieter SC, Jukema JW, Umans VAWM, Schalij MJ, van Boven AJ (2013) Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol 112(12):1867–1872PubMedGoogle Scholar
  12. 12.
    Sulpher J, Dattilo F, Dent S, Turek M, Reaume MN, Johnson C. Acute cardiogenic shock induced by infusional 5-fluorouracil. Case Rep Oncol Med 2014;2014:819396Google Scholar
  13. 13.
    Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37(36):2768–2801PubMedGoogle Scholar
  14. 14.
    Manual of cardio-oncology. Cardiovascular care in the cancer patient. 2017 ed: Springer International Publishing Switzerland 2017; 2017Google Scholar
  15. 15.
    Ozaki T, Chiba S, Annen K, Kawamukai Y, Kohno N, Horimoto M (2010) Acute coronary syndrome due to coronary artery compression by a metastatic cardiac tumor. J Cardiol Cases 1(1):e52–ee5PubMedGoogle Scholar
  16. 16.
    Nogales-Romo MT, Tirado G, Freitas-Ferraz A, Martínez-Losas P, Rodrigo JL, Alswies A, Saiz-Pardo M, Ruiz-Mateos B, Viana-Tejedor A, Fernández-Ortiz A, Macaya C, Núñez-Gil IJ (2016) Coronary embolism of left atrial myxoma coexisting with severe aortic stenosis and atherosclerotic coronary disease. Int J Cardiol 203:315–316PubMedGoogle Scholar
  17. 17.
    Noguchi M, Yamada Y, Sakakura K, Katayama T, Momomura S, Ako J (2016) Coronary thrombus aspiration revealed tumorous embolism of myxofibrosarcoma from the left atrium. Cardiovasc Interv Ther 31(1):75–78PubMedGoogle Scholar
  18. 18.
    Antonopoulos AS, Chrysohoou C, Lymperiadis D, Brili S, Tousoulis D (2016) Peripheral and coronary artery embolisms due to left ventricle fibroelastoma. Hell J Cardiol 57(5):368–370Google Scholar
  19. 19.
    Aronson D, Brenner B (2018) Arterial thrombosis and cancer. Thromb Res 164(Suppl 1):S23–Ss8PubMedGoogle Scholar
  20. 20.
    Farmakis D, Mantzourani M, Filippatos G (2018) Anthracycline-induced cardiomyopathy: secrets and lies. Eur J Heart Fail 20(5):907–909PubMedGoogle Scholar
  21. 21.
    Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 131(22):1981–1988PubMedGoogle Scholar
  22. 22.
    Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Y.-Hassan S, Migliore F, Horowitz JD, Shimokawa H, Lüscher TF, Templin C International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J 2018;39(22):2032–2046PubMedPubMedCentralGoogle Scholar
  23. 23.
    Giza DE, Lopez-Mattei J, Vejpongsa P et al (2017) Stress-induced cardiomyopathy in cancer patients. Am J Cardiol 120(12):2284–2288Google Scholar
  24. 24.
    Munoz E, Iliescu G, Vejpongsa P, Charitakis K, Karimzad K, Lopez-Mattei J, Yusuf SW, Marmagkiolis K, Iliescu C (2016) Takotsubo stress cardiomyopathy: “good news” in cancer patients? J Am Coll Cardiol 68(10):1143–1144PubMedGoogle Scholar
  25. 25.
    Fernandez SF BM, Canty JM Jr. Takotsubo cardiomyopathy following initial chemotherapy presenting with syncope and cardiogenic shock – a case report and literature review. J Clin Exp Cardiol 2:124 2011Google Scholar
  26. 26.
    Burgdorf C, Kurowski V, Bonnemeier H, Schunkert H, Radke PW (2008) Long-term prognosis of the transient left ventricular dysfunction syndrome (Tako-Tsubo cardiomyopathy): focus on malignancies. Eur J Heart Fail 10(10):1015–1019Google Scholar
  27. 27.
    Madias JE (2016) What is/are the trigger(s) of takotsubo syndrome in cancer patients receiving chemotherapy? Int J Cardiol 222:253PubMedGoogle Scholar
  28. 28.
    Franco TH, Khan A, Joshi V, Thomas B (2008) Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag 4(6):1367–1370PubMedPubMedCentralGoogle Scholar
  29. 29.
    Santos JRU, Brofferio A, Viana B, Pacak K (2018) Catecholamine-induced cardiomyopathy in pheochromocytoma: how to manage a rare complication in a rare disease? Horm Metab ResGoogle Scholar
  30. 30.
    Bergland BE (1989) Pheochromocytoma presenting as shock. Am J Emerg Med 7(1):44–48PubMedGoogle Scholar
  31. 31.
    Assefa D, Welsch J, Laubner K, Burgdorf C, Kotzerke M (2015) Cardiogenic shock due to atypical Tako-Tsubo cardiomyopathy in a young woman with pheochromocytoma. Deutsche medizinische Wochenschrift (1946). 140(6):422–425Google Scholar
  32. 32.
    Chiang YL, Chen PC, Lee CC, Chua SK (2016) Adrenal pheochromocytoma presenting with Takotsubo-pattern cardiomyopathy and acute heart failure: a case report and literature review. Medicine. 95(36):e4846PubMedPubMedCentralGoogle Scholar
  33. 33.
    Di Palma G, Daniele GP, Antonini-Canterin F, Piazza R, Nicolosi GL (2010) Cardiogenic shock with basal transient left ventricular ballooning (Takotsubo-like cardiomyopathy) as first presentation of pheochromocytoma. J Cardiovasc Med (Hagerstown) 11(7):507–510Google Scholar
  34. 34.
    Law C, Khaliq A, Guglin M (2013) Reversible cardiogenic shock due to catecholamine-induced cardiomyopathy: a variant of takotsubo? Am J Emerg Med 31(11):1621.e1–1621.e3Google Scholar
  35. 35.
    Hekimian G, Kharcha F, Brechot N et al (2016) Extracorporeal membrane oxygenation for pheochromocytoma-induced cardiogenic shock. Ann Intensive Care 6(1):117PubMedPubMedCentralGoogle Scholar
  36. 36.
    Flam B, Broome M, Frenckner B, Branstrom R, Bell M (2015) Pheochromocytoma-induced inverted takotsubo-like cardiomyopathy leading to cardiogenic shock successfully treated with extracorporeal membrane oxygenation. J Intensive Care Med 30(6):365–372PubMedGoogle Scholar
  37. 37.
    Tsibiribi P, Bui-Xuan C, Bui-Xuan B, Lombard-Bohas C, Duperret S, Belkhiria M, Tabib A, Maujean G, Descotes J, Timour Q (2006) Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol 25(6):305–309PubMedGoogle Scholar
  38. 38.
    Sasson Z, Morgan CD, Wang B, Thomas G, MacKenzie B, Platts ME (1994) 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol 10(8):861–864PubMedGoogle Scholar
  39. 39.
    Sellier-Leclerc AL, Belli E, Guerin V, Dorfmuller P, Deschenes G (2013) Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol 28(9):1875–1879PubMedGoogle Scholar
  40. 40.
    Alonso JJ, Canovas A, Rubio G (2013) Lethal enterovirus myocarditis associated with rituximab and chemotherapy for follicular lymphoma. Med Clin 141(10):459–460Google Scholar
  41. 41.
    Asnani A (2018) Cardiotoxicity of immunotherapy: incidence, diagnosis, and management. Curr Oncol Rep 20(6):44PubMedGoogle Scholar
  42. 42.
    Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Eng J Med 375(18):1749–1755Google Scholar
  43. 43.
    Sauer R, Kiewe P, Desole M et al (2017) Lymphocytic myocarditis in a patient with metastatic clear cell renal cell carcinoma treated with nivolumab. Pathologe 38(6):535–539PubMedGoogle Scholar
  44. 44.
    Cheung CC, Constantine M, Ahmadi A, Shiau C, Chen LYC (2017) Eosinophilic myocarditis. Am J Med Sci 354(5):486–492PubMedGoogle Scholar
  45. 45.
    Biedka M, Ziolkowska E, Windorbska W (2012) Acute pulmonary embolus in the course of cancer. Contemp Oncol 16(5):388–393Google Scholar
  46. 46.
    Silva P, Rosales M, Milheiro MJ, Santos LL (2015) Pulmonary embolism in ambulatory oncologic patients. Acta Med Port 28(4):463–468PubMedGoogle Scholar
  47. 47.
    Bach AG, Neumann J, Taute BM, Surov A (2016) Frequency, cause, and awareness of pulmonary embolism in oncologic patients. Dtsch Med Wochenschr 141(10):713–717PubMedGoogle Scholar
  48. 48.
    Jones DH, Schlatter MG, Cornelius AS, Neirotti RA (2000) A massive pulmonary tumor embolism after surgical manipulation and biopsy of a pelvic mass. Anesth Analg 90(2):322–323PubMedGoogle Scholar
  49. 49.
    Choi EJ, Jin GY (2017) Pulmonary embolism after percutaneous cryoablation for lung cancer: a case report. J Vasc Interv Radiol 28(9):1285–1287PubMedGoogle Scholar
  50. 50.
    Lin HF, Liao KF, Chang CM, Lin CL, Lai SW, Hsu CY (2018) Correlation of the tamoxifen use with the increased risk of deep vein thrombosis and pulmonary embolism in elderly women with breast cancer: a case-control study. Medicine. 97(51):e12842PubMedPubMedCentralGoogle Scholar
  51. 51.
    Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A (2011) Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist 16(4):432–444PubMedPubMedCentralGoogle Scholar
  52. 52.
    Bois MC, Eckhardt MD, Cracolici VM et al (2018) Neoplastic embolization to systemic and pulmonary arteries. J Vasc Surg 68(1):204–212 e7PubMedGoogle Scholar
  53. 53.
    von Herbay A, Illes A, Waldherr R, Otto HF (1990) Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer. 66(3):587–592Google Scholar
  54. 54.
    Han S, Kreit J (2013) 1242: Cardiogenic shock from pulmonary tumor thrombotic microangiopathy. 41(12):A319Google Scholar
  55. 55.
    Ohguchi H, Imaeda K, Hotta A, Kakoi S, Yasuda S, Shimizu Y, Hayakawa A, Mishina H, Hasegawa C, Ito S, Ogawa K, Yagi T, Koyama H, Tanaka T, Kato H, Takahashi S, Joh T (2018) An autopsy case of pulmonary tumor thrombotic microangiopathy due to rapidly progressing colon cancer in a patient with type 2 diabetes. Intern Med 57(17):2533–2539PubMedPubMedCentralGoogle Scholar
  56. 56.
    Vincent F, Lamblin N, Classe M, Schurtz G, Rauch A, Fertin M, de Groote P (2017) Subacute right heart failure revealing three simultaneous causes of post-embolic pulmonary hypertension in metastatic dissemination of breast cancer. ESC Heart Fail 4(1):75–77PubMedGoogle Scholar
  57. 57.
    Seol SH, Park BM, Jin HY, Kim DI (2013) Fatal acute right heart failure in gastric cancer patients. Heart Views 14(4):179–181PubMedPubMedCentralGoogle Scholar
  58. 58.
    Okubo Y, Wakayama M, Kitahara K, Nemoto T, Yokose T, Abe F, Hiruta N, Sasai D, Shinozaki M, Nakayama H, Ishiwatari T, Shibuya K (2011) Pulmonary tumor thrombotic microangiopathy induced by gastric carcinoma: morphometric and immunohistochemical analysis of six autopsy cases. Diagn Pathol 6:27PubMedPubMedCentralGoogle Scholar
  59. 59.
    Tsujimoto N, Miyoshi A, Mimura M, Naka T, Yamasaki M, Yokoi T (2018) Case report: pulmonary tumor thrombotic microangiopathy in a cervical cancer patient. Gynecol Obstet Investig 83(1):99–104Google Scholar
  60. 60.
    Purga SL, Narula N, Horn EM, Karas MG (2015) Pulmonary tumour thrombotic microangiopathy as a cause of new-onset pulmonary hypertension in a patient with metastatic low-grade serous ovarian cancer. BMJ Case Rep 2015Google Scholar
  61. 61.
    Takayama T, Okura Y, Okada Y, Honma K, Nashimoto A, Sato N, Yokoyama A, Minamino T (2015) Characteristics of neoplastic cardiac tamponade and prognosis after pericardiocentesis: a single-center study of 113 consecutive cancer patients. Int J Clin Oncol 20(5):872–877PubMedGoogle Scholar
  62. 62.
    Khan UA, Shanholtz CB, McCurdy MT (2017) Oncologic mechanical emergencies. Hematol Oncol Clin North Am 31(6):927–940PubMedGoogle Scholar
  63. 63.
    Abdelnaby M, Almaghraby A, Saleh Y, Abayazeed R (2018) Pericardial sarcoma. BMJ Case Rep 2018Google Scholar
  64. 64.
    Chen YY, Huang WC, Huang MH, Lu TM, Hsu CP (2018) The intra-pericardial paraganglioma presenting as ascites and hemopericardium with impending tamponade. Int Heart J 59(3):664–667PubMedGoogle Scholar
  65. 65.
    Nagarsheth NP, Harrison M, Kalir T, Rahaman J (2006) Malignant pericardial effusion with cardiac tamponade in a patient with metastatic vaginal adenocarcinoma. Int J Gynecol Cancer 16(3):1458–1461PubMedGoogle Scholar
  66. 66.
    Oka Y, Okada K, Miyake Y, et al. [Three cases of gastric cancer with rare presentation of oncologic emergency]. Gan to kagaku ryoho Cancer & chemotherapy 2016;43(12):2398–2400Google Scholar
  67. 67.
    Chen X, Miao Q, Yu Y et al Blunt trauma-induced pericardial tamponade after video-assisted thoracoscopic surgery. Ann Thorac SurgGoogle Scholar
  68. 68.
    Chung MW, Ha SY, Choi JH, Park HJ, Myung DS, Cho SB, Lee WS, Kim JW, Oh HH, Joo YE (2018) Cardiac tamponade after radiofrequency ablation for hepatocellular carcinoma: case report and literature review. Medicine. 97(49):e13532PubMedPubMedCentralGoogle Scholar
  69. 69.
    Gonzalo Baron Esquivias RA (2015) Cardiac management of oncology patients. SpringerGoogle Scholar
  70. 70.
    Sundaram VR, Abbas T (2018) Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: case report. Medicine. 97(44):e12751PubMedPubMedCentralGoogle Scholar
  71. 71.
    Burkhart T, Keith MCL, Lenneman CAG, Fernando RR (2018) Bortezomib-induced cardiac tamponade in a 49-year-old man. Tex Heart Inst J 45(4):260–263PubMedPubMedCentralGoogle Scholar
  72. 72.
    Asai M, Kato Y, Kawai S, et al. Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report2019Google Scholar
  73. 73.
    Zhao Y, Liu S (2017) Acute cardiac herniation after left Intrapericardial pneumonectomy. J Cardiothorac Vasc Anesth 31(1):270–273PubMedGoogle Scholar
  74. 74.
    Alimi F, Marzouk M, Mgarrech I, Chemchik H, Limayem F (2016) Cardiac herniation after left intrapericardial pneumonectomy. Asian Cardiovasc Thorac Ann 24(6):590–592PubMedGoogle Scholar
  75. 75.
    Zandberg FT, Verbeke SJ, Snijder RJ, Dalinghaus WH, Roeffel SM, Van Swieten HA (2004) Sudden cardiac herniation 6 months after right pneumonectomy. Ann Thorac Surg 78(3):1095–1097PubMedGoogle Scholar
  76. 76.
    Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM (2017) Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 5(1):91PubMedPubMedCentralGoogle Scholar
  77. 77.
    Keenan NG, Nicholson AG, Oldershaw PJ (2008) Fatal acute pulmonary hypertension caused by pulmonary tumour thrombotic microangiopathy. Int J Cardiol 124(1):e11–e13PubMedGoogle Scholar
  78. 78.
    Miyazaki S, Ikeda T, Ito G, Inoue M, Nara K, Nishinaga Y, Hasegawa Y (2017) Pulmonary tumor thrombotic microangiopathy successfully treated with corticosteroids: a case report. J Med Case Rep 11(1):356PubMedPubMedCentralGoogle Scholar
  79. 79.
    Ogawa A, Yamadori I, Matsubara O, Matsubara H (2013) Pulmonary tumor thrombotic microangiopathy with circulatory failure treated with imatinib. Intern Med 52(17):1927–1930PubMedGoogle Scholar
  80. 80.
    Higo K, Kubota K, Takeda A, Higashi M, Ohishi M (2014) Successful antemortem diagnosis and treatment of pulmonary tumor thrombotic microangiopathy. Intern Med 53(22):2595–2599PubMedGoogle Scholar
  81. 81.
    Reynen K, Kockeritz U, Strasser RH (2004) Metastases to the heart. Ann Oncol 15(3):375–381PubMedGoogle Scholar
  82. 82.
    Lestuzzi C (2010) Neoplastic pericardial disease: old and current strategies for diagnosis and management. World J Cardiol 2(9):270–279PubMedPubMedCentralGoogle Scholar
  83. 83.
    Farmakis D, Keramida K, Filippatos G (2018) How to build a cardio-oncology service? Eur J Heart Fail 20(12):1732–1734PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Medical School University of CyprusNicosiaCyprus
  2. 2.Cardio-Oncology Clinic, Heart Failure Unit, Second Department of Cardiology, Attikon University HospitalNational and Kapodistrian University of AthensAthensGreece
  3. 3.Emergency Institute for Cardiovascular Diseases “Prof. C.C.Iliescu”, BucharestUniversity of Medicine Carol Davila BucharestBucharestRomania

Personalised recommendations